Central Neurocytoma (WHO Grade II)

Synonyms
central neurocytoma

Central neurocytoma is a rare WHO Grade 2 tumor that typically occurs in the lateral ventricle. In rare cases, central neurocytomas can also occur in the third ventricle1. The most common initial presentation is caused by increased intracranial pressure or ventriculomegaly.

WHO Classification

According to the WHO classification, central neurocytomas belong to the group of glioneuronal and neuronal tumors and are classified as WHO Grade 2.

Epidemiology

Central neurocytoma accounts for approximately 0.1 - 0.5 % of all brain tumors. Incidence is highest in the third decade of life. However, central neurocytoma can occur at any age, with an equal distribution between women and men.

Localization

Central neurocytoma typically arises from the septum pellucidum, the fornix, or the wall of the lateral ventricle2.

Symptoms

Central neurocytomas usually become symptomatic through symptoms of increased intracranial pressure: headache, vomiting, nausea, visual deficits, or papilledema. Epileptic seizures, memory impairment, or motor deficits may also occur3.

Imaging

CT Imaging

On CT imaging, calcifications are present in 25-50 % of central neurocytomas, which typically appear iso- to hyperdense, with hypodense areas corresponding to cystic changes4. On contrast-enhanced sequences, the tumor demonstrates moderate to intense contrast enhancement5.

MRI Imaging

On MRI, central neurocytomas appear heterogeneously isointense on T1-weighted sequences and hyperintense on T2-weighted sequences. MR spectroscopy frequently demonstrates a high glycine peak6. MRI also shows moderate to intense contrast enhancement of the tumor7.

Central neurocytoma WHO Grade II MRI
Visualization of a histopathologically confirmed central neurocytoma (WHO Grade II) on different MRI sequences.

Treatment

Complete tumor resection is often curative, and additional radiation therapy is usually not necessary after a gross total resection (GTR)8. In cases of subtotal resection, surgical treatment can be combined with stereotactic radiation therapy9 10 11 12. After successful treatment, long-term follow-up with imaging should be performed to rule out recurrence13.

References


    Editorial transparency

    Authorship & revisions

    Who created and updated this article, and which changes are documented.

    Article created by
    Last edited:
    on
    Revision history
    6 edits · 1 contributor
    Author list:
    Show revision history 6 entries

    6 edits by 1 author

    Edit · Alaric Steinmetz · (+1 −1)

    No content change recorded

    Edit · Alaric Steinmetz ·

    No content change recorded

    Edit · Alaric Steinmetz · (+64 −0)

    No content change recorded

    Edit · Alaric Steinmetz · (+0 −62)

    No content change recorded

    Edit · Alaric Steinmetz ·

    No content change recorded

    Article created on · Alaric Steinmetz

    Image viewer

    Image

    Open original